OREX : Analysis & Opinions

  1. Orexigen Therapeutics, Inc. (OREX): New Analyst Report from Zacks ...

    January 16, 2015
    Orexigen swung to a profit in the third quarter of 2014 with earnings coming in at $0.09 per share, beating the Zacks Consensus ...
  2. 4 Biotech Stocks that Doubled in 2014 - Analyst Blog

    December 26, 2014
    Promising pipeline candidates, progress on the regulatory front and interesting research platforms helped these 4 biotech ...
  3. Novo Nordisk's Saxenda Gets FDA Nod, Launch in 1H15 - Analyst ...

    December 24, 2014
    Novo Nordisk's (NVO) Saxenda received FDA approval as the first once-daily human glucagon-like peptide-1 analogue for chronic ...
  4. Orexigen's Obesity Drug Mysimba Gets CHMP Nod - Analyst Blog

    December 22, 2014
    The CHMP gave a positive opinion on the approval of Orexigen's (OREX) weight loss drug, Mysimba.
  5. 4 Top Ranked Biotech Stocks that Beat the Market in 2014 - Analyst ...

    December 16, 2014
    Despite the sell-off in late March, the biotech sector bounced back thanks to important product approvals, mergers and acquisitions, ...
  6. Update on Orexigen's Contrave - Analyst Blog

    January 10, 2013
    Orexigen Therapeutics, Inc. (OREX) recently provided an update on its obesity candidate, Contrave. The company, which had ...
  7. Arena Pharmaceuticals – One Huge Step Forward, But Many More ...

    June 28, 2012
    ARNA shareholders got some major validation on June 27, 2012, when the company announced that the FDA had formally approved ...
  8. Wall Street Isn't Buying The Medifast Story

    March 5, 2012
    Medifast gets a lot of doubt on the Street.
  9. Arena's New Data Doesn't Change Obesity Pill Outlook

    May 30, 2011
    Arena's new data isn't new and doesn't address the company's biggest issues.
  10. FDA's Bizarro World - Orexigen Gets Panel Approval!

    December 8, 2010
    In a surprise decision, an FDA panel votes to approve Contrave, Orexigen's new obesity drug.
  11. FDA To Obesity Drugs: Drop Dead

    September 20, 2010
    An FDA panel knocks down yet another would-be obesity drug.
  12. Can Investors Fatten Up On Weight Loss?

    June 22, 2010
    Obesity is described as a multi-billion dollar crisis in North America, but how can investors profit from the solutions?
  13. Five Must-Ask Questions Before Taking The IPO Bait

    May 16, 2008
    IPOs often make great discussion but lousy investments. Learn how to avoid getting burned.
Trading Center